PPRO024-001_Sunshine Study

This phase III study focuses on the safety and evaluation of clinical parameters of 12 weeks of home self-infusion therapy with Prolastin® in patients suffering from severe alpha-1-antitrypsin deficiency. (2024-515894-80)

D5180C00047_ARRIVALhttps://euclinicaltrials.eu/search-for-clinical-trials

Phase 3b, open-label study with tezepelumab to reduce inhaled background medication in severe asthma. As part of the study, patients must present to the Clinical Department every 4 weeks, and blood tests and lung function diagnostics are carried out. (EU CT No. 2024-512113-41-00)

AR-DEX-22-02_EXHALE-3https://clinicaltrials.gov/study/NCT05813288

Phase 3, A randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and tolerability of orally administered dexpramipexole over a 52-week period in participants with severe eosinophilic asthma. Laboratory values, lung function tests and ECGs will be performed as part of the study. Conditions for inclusion include stable asthma therapy, evidence of eosinophils and 2 documented exacerbations in the last 12 months. (EudraCT: 2023-503693-20)

INCB 54707-208https://clinicaltrials.gov/study/NCT05851443

A placebo-controlled phase 2 study of the efficacy and safety of oral povorcitinib in patients with poorly controlled severe asthma. Prerequisites for study inclusion include 2 documented exacerbations. Current therapy with biologics is an exclusion criterion. Lung function parameters, blood values and questionnaires are collected regularly over 52 weeks as part of the studies. (EudraCT: 2022-502570-16-00)

AIRPOWER https://clinicaltrials.gov/study/NCT06422078

A non-interventional, prospective study with benralizumab in severe eosinophilic asthma. Data will be collected from daily life. The study will run for 52 weeks, during which the patient must attend approximately 5 visits to the Clinical Department. (NCT06422078)

ERADICATEhttps://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002335-33

Inhaled ColiFin® in adult patients with bronchiectasis disease and new asymptomatic Pseudomonas aeruginosa infection. Patients inhale Colifin over a period of 28 days. Prerequisite for inclusion is the first positive sputum culture for PA no longer than 12 weeks ago. (EudraCT: 2021-002335-33)

BI1397-0014_Airtivityhttps://www.clinicaltrials.gov/study/NCT06872892

A randomized and placebo-controlled phase 3 study on the efficacy, safety and tolerability of oral BI1291583 in patients with bronchiectasis. The study lasts 76 weeks, participation requirement is at least 2 exacerbations in the last 12 months and CT-supported diagnosis (EudraCT: 2024-518589-29).

TEFIBEOShttps://www.clinicaltrialsregister.eu/ctr-search/trial/2022-003584-18

Phase 2 study, administration of tezepelumab s.c. in patients with progressive fibrotic ILD. The prerequisite for inclusion is evidence of blood or BAL eosinophilia. Among other things, lung function parameters and blood values will be determined as part of the study, and a bronchoscopy is also planned. The study will run for 56 weeks and patients will be instructed to administer the injection at home. (EudraCT: 2022-003584-18)

AP01-007_Mist https://clinicaltrials.gov/study/NCT06329401

Phase 2b placebo-controlled study on the efficacy and safety of inhaled pirfenidone in patients with progressive pulmonary fibrosis. The treatment runs for 52 weeks. As part of the study, various examinations (lung function diagnostics, blood sampling, etc.) will be carried out in the Clinical Department. (EU-CT Number: 2023-508429-29-00)

SNDX-6352-0506https://clinicaltrials.gov/study/NCT06132256

Phase 2b placebo-controlled study on the efficacy and safety of axatilimab intravenously in patients with IPF. Study participation comprises 26 weeks, examinations are collected at close intervals. (EU-CT Number: 2022-502954-15-00)

VP-C21-011_ASPIREhttps://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-buloxibutid-for-patients-with-idiopathic-pulmonary-fibrosis/

Phase 2b placebo-controlled study over 52 weeks on the efficacy and safety of buloxibutide in patients with IPF. The study included 4-weekly visits to the Clinical Department for various examinations (EU CT No.: 2023-509069-19).

ENV-IPF-103_WHISTLEhttps://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-taladegib-for-patients-with-idiopathic-pulmonary-fibrosis/

Phase 2, study on the efficacy and safety of oral ENV-101 in patients with IPF. CT scans will be performed as part of the study. One visit to the Clinical Department every 4 weeks. (EU CT No. 2024-511754-41-00)

BI 1305-0046 Fibroneer-Sard

Phase IIIb study on the efficacy and safety of oral nerandomilast over 26 weeks in patients with Sard_ILD. The study involves close monitoring in the Clinical Department, including CT scans and questionnaires to be answered by the patients. (EUCTNo. 2024-512849-17-00)

MK-2870-007https://clinicaltrials.gov/study/NCT06170788

Phase 3 open-label first-line study in metastatic non-small cell lung cancer (PD-L1 > 50%). The efficacy of MK-2870 in combination with pembrolizumab vs. monotherapy pembrolizumab will be tested. (EU CT: 2023-503376-24)

TIGER Meso

Application of Tumor Treating Fields in patients with mesothelioma.

D702BC00001_ArtemideLung02 https://clinicaltrials.gov/study/NCT06692738?rank=1

Phase III trial of first-line therapy with rilvegosomig or pembrolizumab in combination with chemotherapy in NSCLC with PD-L1. (EudraCT: 2024-514281-39-00)

D702FC00001_ArtemideLung03https://clinicaltrials.gov/study/NCT06627647?rank=1

Phase III study of first-line therapy with rilvegosomig or pembrolizumab in combination with chemotherapy in NSCLC with PD-L1. (EU-CT: 2024-515008-38-00)

GCT1046-06 https://clinicaltrials.gov/study/NCT06635824

A prospective, open-label, randomized, parallel-group, phase III study of acasunlimab (GEN1046) in combination with pembrolizumab versus docetaxel in patients with PD-L1-positive metastatic non-small cell lung cancer after treatment with PD1/PD-L1 inhibitor and platinum-containing chemotherapy (EU CT No: 2024-512998-27-00).

Move PCDhttps://www.pcd-ks.info/INFOS/News/Aufruf-zur-Teilnahme-Studie-Move-PCD

In the study, the effect on quality of life of participation in an individualized and supervised activity program is observed in comparison to the sole recommendation for physical activity. The inclusion criterion is the willingness to participate in the activity program and to have weekly telephone contacts as well as to wear the activity meter for one year.

HELP-PCD

To provide evidence for the use of hypertonic saline in people with primary ciliary dyskinesia.

MK5475-013https://classic.clinicaltrials.gov/ct2/show/NCT05612035

Phase 2 study on the efficacy and safety of MK5475 in patients with pulmonary hypertension in combination with COPD. The study may include right heart catheterization, CT and echocardiography. Treatment will be placebo-controlled for 24 weeks, followed by treatment with the verum as part of a follow-up study. (EudraCT: 2022-501201-13-00)